No Data
No Data
[IPO Monthly Report] The Hong Kong IPO market saw a surge in subscription popularity and a significant decrease in the rate of IPOs breaking below the issue price in June. The expectations of the "Big Four" were mixed with both sorrow and joy.
In the first half of 2024, Hong Kong's IPO market continued its recent sluggish trend due to external market factors, global economic uncertainty, and cautious investor sentiment. The "Big Four" lowered their forecast for Hong Kong's annual IPO fundraising at the beginning of the year, but PwC expects Hong Kong's new IPO fundraising to exceed HKD 100 billion this year. PwC stated that the reduction in bearish factors, high demand for funding for business development, and the end of the interest rate hike cycle will bring back funds from Europe, America, and the Middle East to Asia, which is beneficial for market liquidity and valuation improvement. After six months of market baptism, PwC finally gave in and lowered Hong Kong's...
Express News | Shares of AI Drug Researcher Quantumpharm Inc Jump More Than 10% on Hong Kong Debut
Express News | Tencent-Backed Quantumpharm Inc Set to Open up 2% in Hong Kong Debut
Citic Securities, Deutsche Bank, CICC Among Banks That Advised QuantumPharm on IPO
Citic Securities, Deutsche Bank, CICC Among Banks That Advised QuantumPharm on IPO
QuantumPharm Shares Expected to Start Trading on Hong Kong Exchange From June 13
QuantumPharm Shares Expected to Start Trading on Hong Kong Exchange From June 13
QuantumPharm Was Marketing Shares at Price Range of HK$5.03-HK$6.03/Share
QuantumPharm Was Marketing Shares at Price Range of HK$5.03-HK$6.03/Share
No Data